Converge Bio
Converge Bio · converge-bio.com
Converge Bio helps antibody discovery teams research targets and prior art from ChatGPT.
How to install Converge Bio in ChatGPT
- Open the official listing for Converge Bio in the ChatGPT workspace you want to use.
- Choose Install plugin if available. Follow any connection steps for the apps listed on the page.
- Open a new conversation on a supported ChatGPT surface. Select Converge Bio from the plugin options or mention it by name.
How to use Converge Bio
Check the marketplace listing or publisher’s documentation for supported actions and examples.
Ranglistenverlauf
Sieh dir die Reihenfolge im öffentlichen Plugin-Verzeichnis von ChatGPT nach Erfassungsdatum an. Popular ist eine redaktionelle Auswahl. Installations- und Nutzungszahlen werden dort nicht veröffentlicht.
Frequently asked questions
Why is Install plugin missing?
Check your account, workspace, plan and region. If the listing says Desktop only, open it in the ChatGPT desktop app.
Übersicht
Find a Lead: name a protein target (for example PD-L1, HER2 or EGFR) and get ranked antibody leads from the Converge dataset, with a target summary. Open a lead to see its full report: binding, IP, sequence, maturity, developability and immunogenicity. Results show in an interactive table that can expand to full screen. Patent extraction: give a patent number (for example US9193787B2) and Converge extracts every antibody sequence and its measurements from the patent. Extraction runs in the background and usually takes 15 to 60 minutes; a patent Converge already processed returns at once. A card in the chat updates on its own and links to the full results and an XLSX file. You sign in with your Converge Bio account. Converge Bio only accesses data that belongs to that account. Search, report and extraction limits follow your account. Patent extraction needs a work email address. Converge Bio provides research data, not medical advice.
Funktionen
- Find antibody leads for a protein target
- Read antibody lead reports
- Extract antibodies from patents